« Back
Home /
Anti-Human IL-3 (Clone 4815)

Anti-Human IL-3 (Clone 4815)

Item no.	LEIN-I-686-100ug
Manufacturer	Leinco Technologies
Amount	100 ug
Quantity options	100 ug 25 ug 500 ug
Category	Antibodies Primary Antibodies
Type	Antibody Monoclonal
Applications	ELISA
Clone	4815
Specific against	Human (Homo sapiens)
Host	Mouse
Citations	1. Laston, D. et al. (1998) Science 241: 1820
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Applications	Quality Tested by Leinco ELISA Sandwich: This antibody is useful as the capture antibody in a sandwich ELISA. The suggested coating concentration is 2 - 8 µg/ml. A suitable detection antibody is PN:I-758 at a concentration of approximately 0.1-0.4 µg/ml. A suggested standard for this assay is PN:I-185.
Manufacturer - Category	Primary Monoclonal Antibodies>Growth Factors and Cytokines
Manufacturer - Targets	IL-3
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Product Description	IL-3 is a 17 kD pleiotropic cytokine and a member of a family of growth factors that sustains both the proliferation and the development of hematopoietic precursors. It also displays neurotrophic activity and is thought to be associated with neurologic disorders. Signal transmission is assured by high affinity binding to the IL-3 receptor (IL3RA). The receptor contains α and β subunits. IL-3 shares the β subunit with IL-5 and GM-CSF which explains their biological functional similarities. The IL-3/receptor complex induces JAK2/STAT5 cell signalization pathway and it can stimulate both the activation of gene expression and the suppression of apoptosis via transcription factor c‑myc and the Ras pathway, respectively. IL-3 fuels the differentiation of multipotent hematopoietic stem cells into myeloid progenitor cells or lymphoid progenitor cells (when in conjunction with IL-7). Together with other cytokines, including EPO, GM-CSF, and IL-6, IL-3 can stimulate proliferation of all cells in the myeloid lineage. The constitutive expression of IL-3 in some leukemia cell lines (as opposed to selective T-cell expression in response to specific impulses or antigens) is thought to fuel the development of the disease. Post-chemotherapy IL-3 application can promote regeneration of granulocytes and platelets. Furthermore, during high-dose chemotherapy, the combination of IL-3, GM-CSF and stem cell factor increases peripheral blood stem cells. IL-3 is thought to have therapeutic potential in lymphohematopoietic disorders and solid cancers.
Background	IL-3 is a 17 kD pleiotropic cytokine and a member of a family of growth factors that sustains both the proliferation and the development of hematopoietic precursors. It also displays neurotrophic activity and is thought to be associated with neurologic disorders. Signal transmission is assured by high affinity binding to the IL-3 receptor (IL3RA). The receptor contains α and β subunits. IL-3 shares the β subunit with IL-5 and GM-CSF which explains their biological functional similarities. The IL-3/receptor complex induces JAK2/STAT5 cell signalization pathway and it can stimulate both the activation of gene expression and the suppression of apoptosis via transcription factor c‑myc and the Ras pathway, respectively. IL-3 fuels the differentiation of multipotent hematopoietic stem cells into myeloid progenitor cells or lymphoid progenitor cells (when in conjunction with IL-7). Together with other cytokines, including EPO, GM-CSF, and IL-6, IL-3 can stimulate proliferation of all cells in the myeloid lineage. The constitutive expression of IL-3 in some leukemia cell lines (as opposed to selective T-cell expression in response to specific impulses or antigens) is thought to fuel the development of the disease. Post-chemotherapy IL-3 application can promote regeneration of granulocytes and platelets. Furthermore, during high-dose chemotherapy, the combination of IL-3, GM-CSF and stem cell factor increases peripheral blood stem cells. IL-3 is thought to have therapeutic potential in lymphohematopoietic disorders and solid cancers.
Other Applications Reported In Literature	Neutralization: This antibody is useful for neutralization of Human IL-3 bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human IL-3 (at 1.25 ng/ml) is 0.1 - 0.3 µg/ml.
PubMed	IL-3
Manufacturer - Specificity	Clone 4815 recognizes an epitope on human IL-3.
RRID	AB_2830807
Formulation	This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 6.2 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Endotoxin Level	< 0.1 EU/µg as determined by the LAL method
Immunogen	Purified Recombinant Human IL-3 (Accession # P08700)
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-I-686-100ug-safety-datasheet.pdf